US Stock MarketDetailed Quotes
NERV Minerva Neurosciences
- 2.4401
- +0.0501+2.10%
Close May 13 16:00 ET
- 2.5400
- +0.0999+4.09%
Post 16:02 ET
17.06MMarket Cap-550P/E (TTM)
2.4800High2.4075Low13.47KVolume2.4400Open2.3900Pre Close33.10KTurnover0.25%Turnover RatioLossP/E (Static)6.99MShares13.490052wk High-0.47P/B13.26MFloat Cap2.286452wk Low--Dividend TTM5.44MShs Float126.7200Historical High--Div YieldTTM3.03%Amplitude1.2600Historical Low2.4570Avg Price1Lot Size
About Minerva Neurosciences Company
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Company Profile
SymbolNERV
Company NameMinerva Neurosciences
Listing DateJul 1, 2014
Issue Price6.00
Founded2007
CEODr. Remy Luthringer, PhD
MarketNASDAQ
Employees9
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1500 District Avenue
CityBurlington
ProvinceMassachusetts
CountryUnited States of America
Zip Code01803
Phone1-617-600-7373
Company Executives
- Name
- Position
- Salary
- Dr. Remy Luthringer, PhD
- Executive Chairman of the Board and Chief Executive Officer
- 1.27M
- Frederick W. Ahlholm
- Senior Vice President, Chief Financial Officer, Principal Accounting Officer and Secretary
- 741.04K
- Geoffrey Race
- President
- 842.75K
- Dr. Fouzia Laghrissi-Thode, M.D.
- Independent Director
- 46.48K
- Dr. David J. Kupfer, M.D.
- Lead Independent Director
- 48.48K
- Hans Peter Hasler
- Independent Director
- 50.48K
- Jan van Heek
- Independent Director
- 47.98K
- Jeryl L. Hilleman
- Independent Director
- 55.48K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg